<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 16, Issue 01,2024</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>Jan-March</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2024</Year>
<Month>03</Month>
<Day>7</Day>
</PubDate>
<ArticleType>Pharmacology</ArticleType>
<ArticleTitle>Cost variation analysis of herbal phytoconstituents and nutraceuticals as a neuroprotective in neurodegenerative disorders</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>36</FirstPage>
<LastPage>44</LastPage>
<AuthorList>
<Author>
<FirstName>Shashikesh</FirstName>
<LastName>Shukla</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Ashutosh</FirstName>
<LastName>Ranjan</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Shamsher</FirstName>
<LastName>Singh</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI>10.56933/Pharmaspire.2024.16104</DOI>
<Abstract>Objective: The objective of the study was to find out the cost variation among herbal phytoconstituents and nutraceuticals used for the treatment of neurodegenerative disorders.
Background: This paper discusses the cost-variation analysis of herbal phytoconstituents and nutraceuticals used as neuroprotective in neurodegenerative disorders. Neurodegenerative disorders are characterized by the loss of nerve cells in the various regions of the brain, which leads to problems such as cognitive impairments and motor problems. Herbal phytoconstituents and nutraceuticals are frequently used for neurodegenerative disorders. The turnover of the Indian herbal industry is more than Rs 80 billion. There are various pharmaceutical companies with innumerable brands, and there is great variability in the price of herbal phytoconstituents and nutraceutical formulations depending on the brand.
Materials and Methods: The cost variation of various herbal phytoconstituents and nutraceuticals used in neurodegenerative disorders produced by different pharmaceutical companies in India was analyzed. The data was collected by authors from https://amazon. in, https://www.1mg.com, https://kiwla.com, https://netmeds.com, and https://thekiwla.com.
Results: In India, 15 herbal phytoconstituents and nutraceuticals with 45 formulations under 390 brands produced by various pharmaceutical companies are used as neuroprotective. Among all the herbal phytoconstituents and nutraceuticals, the maximum percentage cost variation and cost ratio were found for Brahmi 500 mg. The minimum percentage cost variation and cost ratio were found for panax ginseng 1000 mg.
Conclusion: We can conclude that there is a very high-cost variation in the different marketed formulations of herbal phytoconstituents and nutraceuticals used as neuroprotective in neurodegenerative disorders.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Amyotrophic lateral sclerosis, Herbal phytoconstituent, Neurodegenerative disorder, Nutraceutical</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=15628&title=Cost variation analysis of herbal phytoconstituents and nutraceuticals as a neuroprotective in neurodegenerative disorders</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1. Chi H, Chang HY, Sang TK. Neuronal cell death mechanisms in major neurodegenerative diseases. Int J Mol Sci 2018;19:3082.
2. Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017;9:a028035.
3. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003;4:49-60.
4. Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The global burden of neurological disorders: Translating evidence into policy. Lancet Neurol 2020;19:255-65.
5. Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, et al. Preventing amyotrophic lateral sclerosis: Insights from pre-symptomatic neurodegenerative diseases. Brain 2022;145:27-44.
6. Xu L, Pu J. Alpha?synuclein in Parkinson’s disease: From pathogenetic dysfunction to potential clinical application. Parkinsons Dis 2016;2016:1720621.
7. Raza C, Anjum R. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci 2019;226:77-90.
8. Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol Neurodegener 2019;14:35.
9. Balestrino R, Schapira AH. Parkinson disease. Eur J Neurol 2020;27:27-42.
10. Jellinger KA. Recent update on the heterogeneity of the Alzheimer’s disease spectrum. J Neural Transm 2022;129:1-24.
11. Knopman DS, Amieva H, Petersen RC, Chand;eacute;telat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers 2021;7:33.
12. Perluigi M, Di Domenico F, Barone E, Butterfield DA. mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med 2021;169:382-96.
13. Williams ET, Chen X, Otero PA, Moore DJ. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease. Neurobiol Dis 2022;170:105768.
14. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur J Neurol 2020;27:1918-29.
15. Angelopoulou E, Paudel YN, Piperi C. Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington’s disease. J Mol Med 2020;98:325-34.
16. Talukder P, Jana A, Dhar S, Ghosh S. Huntington’s Chorea-a rare neurodegenerative autosomal dominant disease: Insight into molecular genetics, prognosis and diagnosis. Appl Biochem Biotechnol 2021;193:2634-48.
17. Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington’s disease: Mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 2017;7:a024240.
18. Makkar R, Behl T, Bungau S, Zengin G, Mehta V, Kumar A, et al. Nutraceuticals in neurological disorders. Int J Mol Sci 2020;21:4424.
19. Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf 2020;19:147-57.
20. Lenka A, Di Maria G, Lamotte G, Bahroo L, Jankovic J. Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease. Expert Rev. Neurother 2022;22:489-98.
21. Joshi M, Prabhakar B. Phytoconstituents and pharmacotherapeutic benefits of pitaya: A wonder fruit. J Food Biochem 2020;44:e13260.
22. Vattananupon S, Chadvongvan P, Akarasereenont P, Tapechum S, Tilokskulchai K, Pakaprot N. Brahmi extract attenuated spatial learning and memory impairment and cell death of rat hippocampal CA1 neurons after the 2-VO induced chronic cerebral hypoperfusion. Siriraj Med J 2017;65:105-11.
23. Singh S, Jamwal S, Kumar P. Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity. Neural Regen Res 2017;12:1137-44.
24. Elhadidy ME, Sawie HG, Meguid NA, Khadrawy YA. Protective effect of ashwagandha (Withania somnifera) against neurotoxicity induced by aluminum chloride in rats. Asian Pac J Trop Biomed 2018;8:59-66.
25. Prema A, Janakiraman U, Manivasagam T, Thenmozhi AJ. Neuroprotective effect of lycopene against MPTP induced experimental Parkinson’s disease in mice. Neurosci Lett 2015;599:12-9.
26. Ahmad S, Jo MH, Ikram M, Khan A, Kim MO. Deciphering the potential neuroprotective effects of luteolin against Aand;beta;1–42-Induced Alzheimer’s disease. Int J Mol Sci 2021;22:9583.
27. Li H, Kang T, Qi B, Kong L, Jiao Y, Cao Y, et al. Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of D-galactose/ AlCl3 inducing rats’ model of Alzheimer’s disease. J Ethnopharmacol 2016;179:162-9.
28. Singh S, Kumar P. Neuroprotective activity of curcumin in combination with piperine against quinolinic acid induced neurodegeneration in rats. Pharmacology 2016;97:151-60.
29. Mohammed NA, Abdou HM, Tass MA, Alfwuaires M, Abdel-Moneim AM, Essawy AE. Oral supplements of Ginkgo biloba extract alleviate neuroinflammation, oxidative impairments and neurotoxicity in rotenoneinduced Parkinsonian rats. Curr Pharm Biotechnol 2020;21:1259-68.
30. Teixeira MD, Souza CM, Menezes AP, Carmo MR, Fonteles AA, Gurgel JP, et al. Catechin attenuates behavioral neurotoxicity induced by 6-OHDA in rats. Pharmacol Biochem Behav 2013;110:1-7.
31. Nillert N, Pannangrong W, Welbat JU, Chaijaroonkhanarak W, Sripanidkulchai K, Sripanidkulchai B. Neuroprotective effects of aged garlic extract on cognitive dysfunction and neuroinflammation induced by and;beta;-amyloid in rats. Nutrients 2017;9:24.
32. Mori MA, Delattre AM, Carabelli B, Pudell C, Bortolanza M, Staziaki PV, et al. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson’s disease is mediated by a reduction of inducible nitric oxide synthase. Nutr Neurosci 2018;21:341-51.
33. Jamali B, Entezari M, Babaei N, Hashemi M. and;beta;-carotene has the neuroprotective effects in Parkinson’s disease by regulating mitochondrial apoptotic pathway genes. J Hum Genet 2020;4:e122531.
34. Raj K, Gupta GD, Singh S. l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson’s disease. Drug Chem Toxicol 2022;45:2097-108.
35. Bihaqi SW, Singh AP, Tiwari M. In vivo investigation of the neuroprotective property of Convolvulus pluricaulis in scopolamine-induced cognitive impairments in Wistar rats. Indian J Pharmacol 2011;43:520-5.
36. Sheykhhasan M, Amini R, Asl SS, Saidijam M, Hashemi SM, Najafi R. Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adiposederived stem cells in a rat model of Alzheimer’s disease. Biomed Pharmacother 2022;152:113224.
37. Shalini VT, Neelakanta SJ, Sriranjini JS. Neuroprotection with Bacopa monnieri-a review of experimental evidence. Mol Biol Rep 2021;48:2653-68.
38. Pany S, Pal A, Sahu PK. Neuroprotective effect of quercetin in neurotoxicity induced rats: Role of neuroinflammation in neurodegeneration. Asian J Pharm Clin Res 2014;7:152-6.
39. Zahiruddin S, Basist P, Parveen A, Parveen R, Khan W, Ahmad S. Ashwagandha in brain disorders: A review of recent developments. J Ethnopharmacol 2020;257:112876.
40. Chen D, Huang C, Chen Z. A review for the pharmacological effect of lycopene in central nervous system disorders. Biomed Pharmacother 2019;111:791-801.
41. Kempuraj D, Thangavel R, Kempuraj DD, Ahmed ME, Selvakumar GP, Raikwar SP, et al. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. Biofactors 2021;47:190-7.
42. Majid A. Panax ginseng-a review. Univ Thi-Qar J Sci 2019;7:96-102.
43. Mahmood K, Zia KM, Zuber M, Salman M, Anjum MN. Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: A review. Int J Biol Macromol 2015;81:877-90.
44. Liu Y, Xin H, Zhang Y, Che F, Shen N, Cui Y. Leaves, seeds and exocarp of Ginkgo biloba L. (Ginkgoaceae): A comprehensive review of traditional uses, phytochemistry, pharmacology, resource utilization and toxicity. J Ethnopharmacol 2022;298:115645.
45. Bae J, Kim N, Shin Y, Kim SY, Kim YJ. Activity of catechins and their applications. Biomed Dermatol 2020;4:8.
46. Melguizo-Rodrand;iacute;guez L, Garcand;iacute;a-Recio E, Ruiz C, De Luna-Bertos E, Illescas-Montes R, Costela-Ruiz VJ. Biological properties and therapeutic applications of garlic and its components. Food Funct 2022;13:2415-26.
47. Lange KW. Omega-3 fatty acids and mental health. Global Health J 2020;4:18-30.
48. Bogacz-Radomska L, Harasym J. and;beta;-Carotene-properties and production methods. Food Qual Saf 2018;2:69-74.
49. Tand;uuml;rkand;ouml;zand;uuml; D, ?anlier N. L-theanine, unique amino acid of tea, and its metabolism, health effects, and safety. Crit Rev Food Sci Nutr 2017;57:1681-7.
50. Jalwal P, Singh B, Dahiya J, Khokhara S. A comprehensive review on shankhpushpi a morning glory. Pharma Innov 2016;5:4.
51. Testai L, Martelli A, Flori L, Cicero AF, Colletti A. Coenzyme Q10: Clinical applications beyond cardiovascular diseases. Nutrients 2021;13:1697.</References>
</References>
</Journal>
</Article>
</ArticleSet>